SELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) released its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01, FiscalAI reports.

SELLAS Life Sciences Group Trading Down 0.6%

SELLAS Life Sciences Group stock traded down $0.03 on Tuesday, hitting $5.22. 2,823,922 shares of the stock traded hands, compared to its average volume of 7,219,854. The firm has a market cap of $963.26 million, a P/E ratio of -20.88 and a beta of 2.24. The business’s fifty day simple moving average is $4.95 and its 200 day simple moving average is $3.61. SELLAS Life Sciences Group has a 1 year low of $1.36 and a 1 year high of $6.14.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group raised their price objective on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SLS. Geode Capital Management LLC lifted its stake in shares of SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock worth $4,819,000 after buying an additional 1,379,988 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of SELLAS Life Sciences Group in the second quarter worth approximately $136,000. Rhumbline Advisers bought a new position in shares of SELLAS Life Sciences Group in the second quarter worth approximately $297,000. XTX Topco Ltd bought a new position in shares of SELLAS Life Sciences Group in the second quarter worth approximately $168,000. Finally, New York State Common Retirement Fund bought a new position in shares of SELLAS Life Sciences Group in the second quarter worth approximately $108,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.